

Nicolas Mounier

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2733508/nicolas-mounier-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

161
papers

10,417
citations

54
h-index

100
g-index

173
ext. papers

11,831
ext. citations

4.3
avg, IF

5.11
L-index

#	Paper	IF	Citations
161	Follicular lymphoma international prognostic index. <i>Blood</i> , 2004 , 104, 1258-65	2.2	1348
160	Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4184-90	2.2	1005
159	Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). <i>Blood</i> , 2003 , 101, 4279-84	2.2	428
158	Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. <i>Blood</i> , 2008 , 112, 4824-31	2.2	270
157	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. <i>Lancet, The</i> , 2011 , 378, 1858-67	40	251
156	Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. <i>Blood</i> , 2008 , 111, 4463-70	2.2	237
155	Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. <i>Journal of Clinical Oncology</i> , 2013 , 31, 240-6	2.2	216
154	The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4079-87	2.2	207
153	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2013 , 14, 525-33	21.7	200
152	CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007 , 25, 787-92	2.2	200
151	High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 440-6	2.2	198
150	Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Blood</i> , 2006 , 108, 2540-4	2.2	198
149	Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4462-9	2.2	194
148	Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4402-6	2.2	180
147	A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. <i>JAMA - Journal of the American Medical Association</i> , 2000 , 283, 2816-21	27.4	170
146	Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. <i>Journal of Clinical Oncology</i> , 2002 , 20, 467-75	2.2	154
145	Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. <i>Bone Marrow Transplantation</i> , 2016 , 51, 51-7	4.4	149

144	Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4317-22	2.2	140
143	MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. <i>Blood</i> , 2012 , 119, 4619-24	2.2	123
142	Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. <i>Blood</i> , 2013 , 122, 3251-62	2.2	120
141	Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3614-20	2.2	118
140	AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. <i>Blood</i> , 2006 , 107, 3832-40	2.2	114
139	Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. <i>Blood</i> , 2004 , 103, 1222-8	2.2	114
138	Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. <i>Blood</i> , 2006 , 108, 4163-9	2.2	103
137	CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications. <i>Blood</i> , 2002 , 99, 2940-7	2.2	101
136	Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5573-9	2.2	100
135	Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. <i>Haematologica</i> , 2013 , 98, 1726-31	6.6	94
134	AIDS-related malignancies: state of the art and therapeutic challenges. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4834-42	2.2	92
133	Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. <i>British Journal of Haematology</i> , 2002 , 119, 726-39	4.5	91
132	Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1732-40	2.2	88
131	Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score B, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 2012 Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2028-36	2.2	88
130	Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1555-63		87
129	PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. <i>Lancet Oncology</i> , 2019 , 20, 202-215	21.7	86
128	Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. <i>Laboratory Investigation</i> , 2004 , 84, 1512-9	5.9	82
127	Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. <i>Lancet Oncology</i> , 2009 , 10, 1160-70	21.7	80

126	Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. <i>Haematologica</i> , 2008 , 93, 1837-42	6.6	79
125	Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. <i>Bone Marrow Transplantation</i> , 2017 , 52, 216-221	4.4	77
124	High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 788-93	4.7	77
123	ABVD (8 cycles) versus BEACOPP (4 escalated cycles \pm baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. <i>Annals of Oncology</i> , 2014 , 25, 1622-8	10.3	74
122	Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. <i>Haematologica</i> , 2011 , 96, 1136-43	6.6	74
121	Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Soci� Fran�aise de Greffe de Moelle et de Th�rapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 78-87	4.7	73
120	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. <i>American Journal of Hematology</i> , 2015 , 90, 197-203	7.1	72
119	BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. <i>Oncotarget</i> , 2012 , 3, 490-501	3.3	66
118	Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3996-4003	2.2	64
117	The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. <i>Cancer</i> , 2007 , 110, 1361-9	6.4	64
116	Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). <i>Annals of Oncology</i> , 2016 , 27, 719-24	10.3	62
115	Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. <i>Annals of Oncology</i> , 2009 , 20, 1985-92	10.3	60
114	FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. <i>Blood</i> , 2017 , 130, 1315-1326	2.2	59
113	Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1854-60	1.9	59
112	Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. <i>Blood</i> , 2007 , 109, 2183-9	2.2	59
111	Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014 , 55, 773-80	1.9	58
110	Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. <i>Annals of Oncology</i> , 2015 , 26, 958-966	10.3	57
109	Numbers of Foxp3-expressing CD4+CD25 ^{high} T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. <i>Experimental Hematology</i> , 2005 , 33, 894-900	3.1	55

108	Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. <i>Blood</i> , 2004 , 103, 695-7	2.2	54
107	Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2826-34	2.2	53
106	Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1309-15	2.2	51
105	(90Y) ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 212-8	2	50
104	Modern management of non-Hodgkin lymphoma in HIV-infected patients. <i>British Journal of Haematology</i> , 2007 , 136, 685-98	4.5	49
103	All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Annals of Oncology</i> , 2004 , 15, 1790-7	10.3	49
102	Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2739-41	2.2	48
101	T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1271-7	2.2	47
100	Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). <i>Cancer</i> , 2009 , 115, 4540-6	6.4	46
99	Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 72, 10-20	7	46
98	Image-guided core-needle biopsy of peripheral lymph nodes allows the diagnosis of lymphomas. <i>European Radiology</i> , 2007 , 17, 843-9	8	45
97	Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells: analysis of 952 autologous peripheral blood stem cell transplantations. <i>Bone Marrow Transplantation</i> , 2007 , 40, 831-5	4.4	44
96	Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010 , 10, 262-9	2	43
95	Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Blood</i> , 2006 , 107, 4636-42	2.2	42
94	GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF- κ B-dependent induction of HIF-1 α . <i>Leukemia</i> , 2015 , 29, 1163-76	10.7	39
93	Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. <i>Annals of Oncology</i> , 2008 , 19, 1875-81	10.3	39
92	Mobile applications in oncology: is it possible for patients and healthcare professionals to easily identify relevant tools?. <i>Annals of Medicine</i> , 2016 , 48, 509-515	1.5	38
91	Personalized medicine in oncology: where have we come from and where are we going?. <i>Pharmacogenomics</i> , 2013 , 14, 931-9	2.6	36

90	Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice. <i>Blood</i> , 2013 , 122, 2402-11	2.2	36
89	High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort. <i>Clinical Infectious Diseases</i> , 2015 , 61, 1469-75	11.6	34
88	Randomized Phase III Study Comparing an Early PET Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study. <i>Blood</i> , 2015 , 126, 577-577	2.2	34
87	Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. <i>Aids</i> , 2017 , 31, 2493-2501	3.5	33
86	A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013 , 163, 334-42	4.5	33
85	Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study. <i>American Journal of Surgical Pathology</i> , 2001 , 25, 297-306	6.7	33
84	GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. <i>Cell Metabolism</i> , 2019 , 29, 1243-1257.e10	24.6	31
83	Non-Hodgkin's lymphoma of the breast: a report of 19 cases and a review of the literature. <i>Clinical Lymphoma and Myeloma</i> , 2005 , 6, 37-42		30
82	Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. <i>Leukemia</i> , 1998 , 12, 213-9	10.7	27
81	Hodgkin lymphoma in patients with HIV infection: a review. <i>Current Hematologic Malignancy Reports</i> , 2012 , 7, 228-34	4.4	25
80	Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. <i>British Journal of Haematology</i> , 2002 , 118, 210-7	4.5	24
79	A multivariate analysis of the survival of patients with aggressive lymphoma. <i>Cancer</i> , 1998 , 82, 1952-1968.	4	22
78	ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup' randomized phase III clinical trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 8002-8002	2.2	22
77	Impact of high-dose chemotherapy on peripheral T-cell lymphomas. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1426-7	2.2	21
76	Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2006 , 91, 715-6	6.6	21
75	Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. <i>Cancer</i> , 2005 , 104, 2735-42	6.4	19
74	Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study. <i>Haematologica</i> , 2015 , 100, 1579-86	6.6	18
73	VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. <i>Cancer</i> , 2008 , 112, 433-42	6.4	18

72	Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. <i>Lancet Haematology, the</i> , 2018 , 5, e403-e410	14.6	17
71	Breast cancer among HIV infected individuals from the ONCOVIH study, in France: therapeutic implications. <i>European Journal of Cancer</i> , 2012 , 48, 3335-41	7.5	16
70	Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine. <i>Blood Cancer Journal</i> , 2013 , 3, e155	7	16
69	LAMP2 expression dictates azacytidine response and prognosis in MDS/AML. <i>Leukemia</i> , 2019 , 33, 1501-1513	15.3	16
68	Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 549-55	3.5	15
67	Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine. <i>American Journal of Hematology</i> , 2013 , 88, 780-3	7.1	14
66	Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012 , 12, 151-4	2	14
65	Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naïve, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest-Est des Leucémies et Autres Maladies du Sang (GOELAMS). <i>Cancer</i> , 2010 , 116, 4299-308	6.4	14
64	Improving Second-Line Therapy in Aggressive Non-Hodgkin's Lymphoma. <i>Seminars in Oncology</i> , 2004 , 31 Suppl 2, 12-16	5.5	14
63	Rituximab: enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma. <i>Seminars in Oncology</i> , 2003 , 30, 28-33	5.5	14
62	Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. <i>Oncotarget</i> , 2016 , 7, 83987-84002	3.3	14
61	Central nervous system involvement in AIDS-related lymphomas. <i>British Journal of Haematology</i> , 2016 , 173, 857-66	4.5	14
60	Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1239-48	1.9	13
59	High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma: a study using patients as their own controls. <i>Cancer</i> , 2007 , 109, 60-7	6.4	13
58	Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. <i>Oncotarget</i> , 2014 , 5, 4384-91	3.3	13
57	Blastic plasmacytoid dendritic cell neoplasm: a report of four cases and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, 1176-81	4.6	12
56	Model-based methodology for analyzing incomplete quality-of-life data and integrating them into the Q-TWiST framework. <i>Medical Decision Making</i> , 2003 , 23, 54-66	2.5	12
55	Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients. <i>Annals of Oncology</i> , 2001 , 12, 1749-55	10.3	12

54	Impact of BMI and Gender on Outcomes in DLBCL Patients Treated with R-CHOP: A Pooled Study from the LYSA. <i>Lymphoma</i> , 2014 , 2014, 1-12		11
53	Hodgkin lymphoma in HIV positive patients. <i>Current HIV Research</i> , 2010 , 8, 141-6	1.3	11
52	Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. <i>Cancer Medicine</i> , 2020 , 9, 6565-6575	4.8	11
51	Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. <i>Cancer</i> , 2019 , 125, 2291-2299	6.4	10
50	FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP). <i>Leukemia</i> , 2004 , 18, 2038-40	10.7	10
49	High-dose therapy for indolent lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 41, 225-39	7	10
48	R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study.. <i>Blood</i> , 2007 , 110, 517-517	2.2	10
47	Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2019 , 17, 115	3	9
46	Relapses, treatments and new drugs. <i>Best Practice and Research in Clinical Haematology</i> , 2012 , 25, 49-60	4.2	9
45	Quantification of urinary allantoin by capillary zone electrophoresis during recombinant urate oxydase (rasburicase) therapy. <i>Clinical Biochemistry</i> , 2006 , 39, 86-90	3.5	9
44	Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. <i>British Journal of Haematology</i> , 2020 , 189, 84-96	4.5	9
43	Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies. <i>Cancer Medicine</i> , 2018 , 7, 539-548	4.8	7
42	Myelodysplasia after autotransplantation. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3446-7	2.2	7
41	Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study. <i>Blood</i> , 2013 , 122, 764-764	2.2	7
40	A multivariate analysis of the survival of patients with aggressive lymphoma 1998 , 82, 1952		7
39	Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era. <i>Current Opinion in Oncology</i> , 2011 , 23, 209-13	4.2	6
38	Lenalidomide In Combination With R-CHOP (R2-CHOP) In Patients With High Burden Follicular Lymphoma: Phase 2 Study. <i>Blood</i> , 2013 , 122, 248-248	2.2	6
37	Managing large cell lymphoma. <i>Annals of Oncology</i> , 2006 , 17 Suppl 4, iv8-11	10.3	5

36	Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era. <i>Aids</i> , 2019 , 33, 993-1000	3.5	5
35	Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2025-31	1.9	4
34	Expression of activating receptors on natural killer cells from AIDS-related lymphoma patients. <i>AIDS Research and Therapy</i> , 2014 , 11, 38	3	4
33	Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. <i>Annals of Oncology</i> , 2008 , 19, 560-5	10.3	4
32	Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. <i>Aids</i> , 2020 , 34, 599-608	3.5	4
31	Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2019 , 21,	6.3	4
30	Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients. <i>Transfusion</i> , 2013 , 53, 115-22	2.9	3
29	New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia. <i>American Journal of Hematology</i> , 2011 , 86, 619-21	7.1	3
28	Prognostic Impact Of Somatic NOTCH2 Mutation In Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2013 , 122, 4247-4247	2.2	3
27	VEGF, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers. <i>Oncotarget</i> , 2017 , 8, 90808-90824	3.3	3
26	Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment. <i>Expert Review of Hematology</i> , 2015 , 8, 205-16	2.8	2
25	Pneumoblastoma: a rare lung tumour occurring as a long-term complication after allogeneic haematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2010 , 45, 197-8	4.4	2
24	Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1668-77	1.9	2
23	A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: results of a phase II study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). <i>Leukemia and Lymphoma</i> , 2007 , 48, 691-8	1.9	2
22	Lymphoplasmocytic malignant lymphoma presenting with spinal epidural involvement: four reports of this uncommon lesion. <i>American Journal of Hematology</i> , 1995 , 50, 316-7	7.1	2
21	In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study. <i>British Journal of Haematology</i> , 2020 , 188, 413-423	4.5	2
20	Favorable outcome of HIV-associated Burkitt lymphoma in the modern combined antiretroviral therapy era. <i>European Journal of Cancer</i> , 2020 , 138, 189-192	7.5	2
19	Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2161-2168	1.9	2

18	Prospective evaluation of blood Epstein-Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas. <i>Aids</i> , 2021 , 35, 861-868	3.5	2
17	First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2017 , 52, 310-312 ⁴⁻⁴		1
16	Cancer incidence in the vicinity of a waste incineration plant in the Nice area between 2005 and 2014. <i>Environmental Research</i> , 2020 , 188, 109681	7.9	1
15	Quality of life following treatment for B-cell lymphoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011 , 11, 523-32	2.2	1
14	Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. <i>Oncology Reports</i> , 2005 , 14, 513	3.5	1
13	Angioimmunoblastic T-Cell Lymphoma: A Clinicopathologic Study of 158 Patients Treated in GELA (Groupe d'Etude des Lymphomes de l'Adulte) Trials.. <i>Blood</i> , 2006 , 108, 397-397	2.2	1
12	High Dose Therapy and Autologous Stem Cell Transplantation Still Improves Progression Free Survival in First Relapse for DLBCL in the Rituximab Era: A Study Using Patients as Their Own Controls.. <i>Blood</i> , 2008 , 112, 2191-2191	2.2	1
11	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. <i>Blood</i> , 2015 , 126, 517-517 ²		1
10	Chemotherapy and Interactions with Combination Antiretroviral Therapy 2016 , 207-214		1
9	Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7518-7518	2.2	0
8	Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study. <i>Annals of Hematology</i> , 2021 , 1	3	0
7	Diffuse Large B-Cell Lymphoma 2016 , 39-65		0
6	Reply to C.F. Hess et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 374	2.2	
5	Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2425-8	1.9	
4	PET imaging 2013 , 96-108		
3	AIDS-Related Lymphoma 2013 , 257-266		
2	Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol. <i>Blood</i> , 2018 , 132, 4132-4132	2.2	
1	Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013 , 122, 1568-1568	2.2	

